Table 10.
Adjusted risk factors of side effects experienced by Slovak healthcare workers who received BNT162b2, February–March 2021 (n = 522).
| Gender Female (vs. Male) |
Age 18–30 (vs. ≥ 55) yo |
Age 31 - 54 (vs. ≥ 55) yo |
Illness Yes (vs. No) |
Medication Yes (vs. No) |
Prior Infection Yes (vs. No) |
||
|---|---|---|---|---|---|---|---|
| Injection Site Pain | B (SE) | 0.62 (0.27) | 1.30 (0.43) | 0.68 (0.38) | 0.03 (0.43) | 0.56 (0.42) | 0.26 (0.41) |
| AOR (CI) | 1.86 (1.09–3.19) | 3.68 (1.58–8.57) | 1.97 (0.94–4.13) | 1.03 (0.44–2.40) | 1.75 (0.77–3.99) | 1.30 (0.59–2.89) | |
| Sig. | 0.023 | 0.002 | 0.075 | 0.950 | 0.182 | 0.518 | |
| Injection Site Swelling | B (SE) | 0.16 (0.36) | 2.20 (1.04) | 1.61 (1.04) | 0.00 (0.46) | 0.23 (0.42) | 0.41 (0.38) |
| AOR (CI) | 1.17 (0.58–2.39) | 9.05 (1.17–70) | 5.02 (0.66–38.38) | 1.00 (0.41–2.47) | 1.26 (0.55–2.90) | 1.50 (0.71–3.17) | |
| Sig. | 0.659 | 0.035 | 0.120 | 0.995 | 0.581 | 0.289 | |
| Injection Site Redness | B (SE) | 0.28 (0.41) | 1.94 (1.05) | 1.43 (1.04) | –0.95 (0.50) | 0.93 (0.41) | 0.15 (0.44) |
| AOR (CI) | 1.33 (0.59–2.98) | 6.93 (0.89–54.21) | 4.18 (0.54–32.22) | 0.39 (0.14 –1.03) | 2.53 (1.12–5.68) | 1.16 (0.49–2.75) | |
| Sig. | 0.495 | 0.065 | 0.170 | 0.058 | 0.025 | 0.734 | |
| Local SideE ffects |
B (SE) | 0.68 (0.28) | 1.31 (0.43) | 0.76 (0.38) | –0.14 (0.44) | 0.69 (0.44) | 0.19 (0.41) |
| AOR (CI) | 1.97 (1.15–3.39) | 3.72 (1.59–8.68) | 2.14 (1.01–4.54) | 0.873 (0.37–2.08) | 2.00 (0.85–4.70) | 1.21 (0.54–2.70) | |
| Sig. | 0.014 | 0.002 | 0.047 | 0.759 | 0.113 | 0.641 | |
| Fatigue | B (SE) | 0.86 (0.22) | 1.87 (0.37) | 1.10 (0.35) | –0.14 (0.29) | 0.32 (0.28) | –0.15 (0.27) |
| AOR (CI) | 2.35 (1.52–3.64) | 6.48 (3.13–13.38) | 3.00 (1.52–5.92) | 0.87 (0.49–1.55) | 1.38 (0.80–2.39) | 0.86 (0.51–1.46) | |
| Sig. | < 0.001 | < 0.001 | 0.002 | 0.630 | 0.253 | 0.577 | |
| Headache | B (SE) | 0.68 (0.24) | 1.10 (0.40) | 0.67 (0.38) | 0.28 (0.30) | –0.29 (0.29) | –0.11 (0.28) |
| AOR (CI) | 1.97 (1.23–3.16) | 3.00 (1.38–6.53) | 1.96 (0.93–4.15) | 1.32 (0.73–2.39) | 0.75 (0.43–1.31) | 0.90 (0.52–1.55) | |
| Sig. | 0.005 | 0.006 | 0.079 | 0.354 | 0.305 | 0.692 | |
| Fever | B (SE) | 0.27 (0.31) | 1.31 (0.64) | 0.87 (0.63) | 0.42 (0.40) | –0.52 (0.39) | 0.34 (0.33) |
| AOR (CI) | 1.31 (0.72–2.39) | 3.70 (1.06–12.89) | 2.38 (0.70–8.15) | 1.53 (0.69–3.37) | 0.59 (0.27–1.28) | 1.41 (0.73–2.70) | |
| Sig. | 0.374 | 0.040 | 0.166 | 0.294 | 0.183 | 0.302 | |
| Chills | B (SE) | 0.42 (0.25) | 0.83 (0.45) | 0.53 (0.44) | 0.09 (0.34) | –0.60 (0.32) | 0.61 (0.28) |
| AOR (CI) | 1.52 (0.92–2.50) | 2.29 (0.95–5.52) | 1.70 (0.72–4.00) | 1.10 (0.57–2.14) | 0.55 (0.29–1.03) | 1.85 (1.08–3.17) | |
| Sig. | 0.099 | 0.066 | 0.227 | 0.783 | 0.063 | 0.026 | |
| Muscle Pain | B (SE) | 0.31 (0.24) | 0.90 (0.43) | 0.74 (0.42) | 0.63 (0.32) | –0.50 (0.31) | 0.39 (0.28) |
| AOR (CI) | 1.36 (0.84–2.19) | 2.45 (1.05–5.69) | 2.10 (0.93–4.74) | 1.88 (1.01–3.53) | 0.61 (0.33–1.11) | 1.48 (0.86–2.55) | |
| Sig. | 0.209 | 0.038 | 0.074 | 0.048 | 0.107 | 0.153 | |
| Joint Pain | B (SE) | 0.65 (0.32) | 0.44 (0.47) | 0.38 (0.45) | –0.18 (0.36) | 0.54 (0.33) | 0.40 (0.32) |
| AOR (CI) | 1.91 (1.02–3.60) | 1.56 (0.62–3.91) | 1.47 (0.61–3.52) | 0.83 (0.42–1.67) | 1.71 (0.90–3.27) | 1.49 (0.80–2.78) | |
| Sig. | 0.045 | 0.347 | 0.390 | 0.606 | 0.102 | 0.207 | |
| Nausea | B (SE) | 0.32 (0.39) | –0.02 (0.68) | 0.62 (0.63) | 0.31 (0.51) | –0.79 (0.51) | –0.15 (0.46) |
| AOR (CI) | 1.38 (0.64–2.95) | 0.98 (0.26–3.73) | 1.86 (0.54–6.44) | 1.37 (0.51–3.70) | 0.46 (0.17–1.23) | 0.86 (0.35–2.13) | |
| Sig. | 0.411 | 0.973 | 0.329 | 0.537 | 0.120 | 0.742 | |
| Malaise | B (SE) | 0.32 (0.28) | 1.55 (0.56) | 0.90 (0.55) | 0.53 (0.36) | –0.39 (0.35) | 0.41 (0.30) |
| AOR (CI) | 1.38 (0.80–2.37) | 4.71 (1.57–14.11) | 2.46 (0.84–7.24) | 1.70 (0.85–3.42) | 0.68 (0.35–1.34) | 1.51 (0.84–2.73) | |
| Sig. | 0.247 | 0.006 | 0.103 | 0.136 | 0.263 | 0.170 | |
| Lymphadenopathy | B (SE) | 0.66 (0.50) | 18.93 (5481) | 18.99 (5481) | 0.61 (0.50) | 0.29 (0.48) | 0.56 (0.43) |
| AOR (CI) | 1.94 (0.73–5.16) | 16.64 × 106 | 17.71 × 106 | 1.85 (0.70–4.89) | 1.34 (0.52–3.46) | 1.75 (0.76–4.03) | |
| Sig. | 0.183 | 1.00 | 1.00 | 0.217 | 0.544 | 0.193 | |
| Systemic Side Effects |
B (SE) | 1.07 (0.23) | 1.86 (0.36) | 1.26 (0.33) | –0.08 (0.33) | 0.147 (0.31) | 0.04 (0.31) |
| AOR (CI) | 2.90 (1.86–4.54) | 6.40 (3.14–13.02) | 3.54 (1.86–6.74) | 0.93 (0.49–1.75) | 1.16 (0.63–2.14) | 1.04 (0.57–1.89) | |
| Sig. | < 0.001 | < 0.001 | < 0.001 | 0.810 | 0.638 | 0.896 | |
| General Side Effects |
B (SE) | 0.83 (0.34) | 1.37 (0.49) | 1.08 (0.43) | –0.01 (0.53) | 0.09 (0.51) | 1.07 (0.74) |
| AOR (CI) | 2.28 (1.18–4.44) | 3.94 (1.51–10.29) | 2.93 (1.27–6.77) | 0.99 (0.36–2.78) | 1.10 (0.40–2.98) | 2.92 (0.68–12.54) | |
| Sig. | 0.015 | 0.005 | 0.012 | 0.990 | 0.855 | 0.149 | |
| Oral Side Effects |
B (SE) | 0.60 (0.43) | 1.34 (1.06) | 2.02 (1.03) | 0.13 (0.47) | –0.19 (0.45) | –0.71 (0.54) |
| AOR (CI) | 1.83 (0.79–4.22) | 3.82 (0.48–30.72) | 7.56 (1.00–57.08) | 1.14 (0.45–2.87) | 0.83 (0.34–2.01) | 0.49 (0.17–1.43) | |
| Sig. | 0.158 | 0.208 | 0.050 | 0.780 | 0.679 | 0.191 | |
| Skin-related Side Effects | B (SE) | 0.87 (0.76) | 17.11 (5509) | 17.92 (5509) | –0.32 (0.85) | –0.29 (0.76) | 0.52 (0.59) |
| AOR (CI) | 2.38 (0.53–10.63) | 26.90 × 106 | 60.71 × 106 | 0.73 (0.14–3.85) | 0.75 (0.17–3.34) | 1.68 (0.53–5.32) | |
| Sig. | 0.256 | 1.00 | 1.00 | 0.707 | 0.703 | 0.376 |
Binary logistic regression was used with a significance level (Sig.) of < 0.05. B = regression coefficient; SE = standard error; AOR = adjusted odds ratio; CI = confidence level of 95%.